Devyser Diagnostics AB publishes quarterly report for the period April to June 2024
“Devyser continued to report high sales growth in the second quarter. Organic growth compared with...
News | June 17, 2024
Devyser Diagnostics AB (publ) today announced that the company has expanded its exclusive collaboration and distribution agreement with Thermo Fisher Scientific, giving Thermo Fisher exclusive rights to commercialize, under combined brands, Devyser’s post-transplant portfolio of NGS products globally. This expands the previously announced agreement where Thermo Fisher had the exclusive rights to commercialize in North America, Europe, Brazil, and Saudi Arabia.
"The expanded agreement with Thermo Fisher Scientific, the world leader in cutting-edge life science, is a great opportunity for Devyser to expand its post-transplant business further and is a significant milestone for our company. Through this expanded collaboration, clinical labs, clinicians, and patients globally will have broad and fast access to our innovative IVDR-certified NGS-based solutions for the detection of graft rejection in stem cell transplant patients and monitoring donor-derived cell-free DNA in blood samples from kidney transplant patients,” says Fredrik Alpsten, Devyser CEO.
"We are excited to expand the collaboration with Devyser and provide broader access to these post-transplant solutions under our transplant diagnostics One Lambda brand, further enabling our customers around the world to enhance patient surveillance, support graft longevity, and improve quality of life for transplant patients," says Tina Liedtky, President, Transplant Diagnostics, Thermo Fisher Scientific.
"Thermo Fisher Scientific is very well positioned to distribute these products globally and with their commercial infrastructure and resources, they can cover all markets quickly and efficiently. Devyser will continue to grow and focus on product development in the transplant field," says Theis Kipling, Devyser CCO.
The agreement includes One Lambda™ Devyser Chimerism for early detection of graft rejection in stem cell transplanted patients and One Lambda™ Devyser Accept cfDNA, a novel test for detecting donor-derived cell-free DNA in kidney transplant patients, as well as the corresponding software solutions.
The One Lambda Devyser transplantation products are CE-IVD certified but not FDA-cleared. Availability in each country depends on local regulatory marketing authorization status. Please consult your local sales representative for details.
For more information, please contact:
Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Telephone: +46 70 667 31 06
Theis Kipling, CCO
E-mail: theis.kipling@devyser.com
Telephone: +46 73 598 07 76
About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.
Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.
Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.
